Inovio Pharmaceuticals (NASDAQ:INO) Announces Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.23, Zacks reports.

Inovio Pharmaceuticals Stock Down 0.5 %

Shares of Inovio Pharmaceuticals stock traded down $0.01 on Tuesday, reaching $2.10. The company’s stock had a trading volume of 595,384 shares, compared to its average volume of 539,758. The company has a market capitalization of $54.81 million, a P/E ratio of -1.00 and a beta of 0.92. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The stock has a 50-day moving average price of $2.05 and a 200-day moving average price of $3.81.

Analysts Set New Price Targets

Several research analysts recently weighed in on INO shares. Oppenheimer reduced their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, HC Wainwright cut their price objective on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $12.40.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.